Medical Oncology

, Volume 29, Issue 2, pp 815–822 | Cite as

MiR-221 expression affects invasion potential of human prostate carcinoma cell lines by targeting DVL2

Original Paper


The aim of this study is to evaluate the effect of the variation of miR-221 on the prostate cancer cells’ NE differentiation and invasive function and to examine the function of miR-221 in plasma as a blood-based miRNA biomarker candidate for CaP. The expression of 7 miRNAs in LNCaP, LNCaP-AI, and PC3 prostate cancer cell lines was detected by Northern blotting. LNCaP and LNCaP-AI cells cultured in androgen-depleted medium were transfected with different synthetic miRs. The ability of invasiveness was evaluated by a Matrigel invasion assay. Cell growth was assessed by using the CCK-8 cell proliferation assay at different times. The expression of NSE and DVL2 during the neuroendocrine phenotype and migration were measured by qRT–PCR and Western blot. The level of miR-221 in the prostate cancer samples was measured by qRT–PCR. MiR-221 was significantly increased compared AIPC with ADPC cell lines. Overexpression of miR-221 in LNCaP cells significantly increased the level of NSE expression and induced NE differentiation. Knocking down the level of miR-221 expression with antagonist miR-221 in the LNCaP-AI cell line increased migration and invasion (P < 0.01). DVL2 protein level was up-regulated after transfection of anti-miR-221. MiR-221 was up-regulated in CaP plasma (P < 0.01). We demonstrate a significant difference in miR-221 expression between ADPC and AIPC. MiR-221 may contribute to NE differentiation, which may be the cause for AIPC. We also suggest that miR-221 may control the migration of AIPC cells through DVL2, working as a key regulator in advanced CaP. The role of miR-221 in other target mRNA needs to be further investigated.


Prostate cancer miR-221 NSE DVL2 









Prostate cancer


Negative control


Dishevelled 2




  1. 1.
    Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics. CA Cancer J Clin. 2007;57:43–66.PubMedCrossRefGoogle Scholar
  2. 2.
    Pienta KJ, Bradley D. Mechanisms underlying the development of androgen- independent prostate cancer. Clin Cancer Res. 2006;12:1665–71.PubMedCrossRefGoogle Scholar
  3. 3.
    Damber JE, Aus G. Prostate cancer. Lancet. 2008;371:1710–21.PubMedCrossRefGoogle Scholar
  4. 4.
    Chen K, Rajewsky N. The evolution of gene regulation by transcription factors and microRNAs. Nat Rev Genet. 2007;8:93–103.PubMedCrossRefGoogle Scholar
  5. 5.
    Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004;116:281–97.PubMedCrossRefGoogle Scholar
  6. 6.
    Lee Y, Kim M, Han J, Yeom KH, Lee S, Baek SH, Kim VN. MicroRNA genes are transcribed by RNA polymerase II. EMBO J. 2004;23:4051–60.PubMedCrossRefGoogle Scholar
  7. 7.
    Ambs S, et al. Genomic profiling of microRNA and messenger RNA reveals deregulated microRNA expression in prostate cancer. Cancer Res. 2008;68:6162–70.PubMedCrossRefGoogle Scholar
  8. 8.
    Galardi S, Mercatelli N, Giorda E, Massalini S, Frajese GV, Ciafre SA, Farace MG. miR-221 and miR-222 expression affects the proliferation potential of human prostate carcinoma cell lines by targeting p27Kip1. J Biol Chem. 2007;282:23716–24.PubMedCrossRefGoogle Scholar
  9. 9.
    Lu J, et al. MicroRNA expression profiles classify human cancers. Nature. 2005;435:834–8.PubMedCrossRefGoogle Scholar
  10. 10.
    Sun T, Wang Q, Balk S, Brown M, Lee GS, Kantoff P. The role of microRNA-221 and microRNA-222 in androgen-independent prostate cancer cell lines. Cancer Res. 2009;69:3356–63.PubMedCrossRefGoogle Scholar
  11. 11.
    Di Sant’Agnese PA, de Mesy Jensen KL. Human prostatic endocrineparacrine (APUD) cells. Distributional analysis with a comparison of serotonin and neuron- specific enolase immunoreactivity and silver stains. Arch Path Lab Med. 1985;109:607–12.PubMedGoogle Scholar
  12. 12.
    Cox ME, Deeble PD, Lakhani S, Parsons SJ. Acquisition of neuroendocrine characteristics by prostate tumor cells is reversible: Implications for prostate cancer progression. Cancer Res. 1999;59:3821–30.PubMedGoogle Scholar
  13. 13.
    Jiborn T, Bjartell A, Abrahamsson PA. Neuroendocrine differentiation in prostatic carcinoma during hormonal treatment. Urology. 1998;51:585–9.PubMedCrossRefGoogle Scholar
  14. 14.
    Tso CL, et al. Androgen deprivation induces selective outgrowth of aggressive hormone refractory prostate cancer clones expressing distinct cellular and molecular properties not present in parental androgen-dependent cancer cells. Cancer J. 2000;6:220–33.PubMedGoogle Scholar
  15. 15.
    Calin GA, et al. Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci USA. 2002;99:15524–9.PubMedCrossRefGoogle Scholar
  16. 16.
    Bonci D, et al. The miR-15a-miR-16–1 cluster controls prostate cancer by targeting multiple oncogenic activities. Nat Med. 2008;14:1271–7.PubMedCrossRefGoogle Scholar
  17. 17.
    Varambally S, et al. Genomic loss of microRNA-101 leads to overexpression of histone methyltransferase EZH2 in cancer. Science. 2008;322:1695–9.PubMedCrossRefGoogle Scholar
  18. 18.
    Li T, Li D, Sha J, Sun P, Huang Y. MicroRNA-21 directly targets MARCKS and promotes apoptosis resistance and invasion in prostate cancer cells. Biochem Biophys Res Commun. 2009;383:280–5.PubMedCrossRefGoogle Scholar
  19. 19.
    Gandellini P, et al. miR-205 Exerts tumor-suppressive functions in human prostate through down-regulation of protein kinase Cepsilon. Cancer Res. 2009;69:2287–95.PubMedCrossRefGoogle Scholar
  20. 20.
    Shi XB, et al. An androgen-regulated miRNA suppresses Bak1 expression and induces androgen independent growth of prostate cancer cells. Proc Natl Acad Sci USA. 2007;104:19983–8.PubMedCrossRefGoogle Scholar
  21. 21.
    Debes JD, Tindall DJ. Mechanisms of androgen-refractory prostate cancer. N Engl J Med. 2004;351:1488–90.PubMedCrossRefGoogle Scholar
  22. 22.
    Mercatelli N, et al. The inhibition of the highly expressed miR-221 and miR- 222 impairs the growth of prostate carcinoma xenografts in mice. PLoS ONE. 2008;3:e4029.PubMedCrossRefGoogle Scholar
  23. 23.
    Bejsovec A. Wnt pathway activation: New relations and locations. Cell. 2005;120:11–4.PubMedGoogle Scholar
  24. 24.
    Cong F, Varmus H. Nuclear-cytoplasmic shuttling of Axin regulates subcellular localization of β-catenin. Proc Natl Acad Sci USA. 2004;101:2882–7.PubMedCrossRefGoogle Scholar
  25. 25.
    Mitchell PS, Rachael K, et al. Circulating microRNAs as stable blood-based markers for cancer detection Proc Natl Acad Sci USA. 2008;105:10513–8.Google Scholar

Copyright information

© Springer Science+Business Media, LLC 2011

Authors and Affiliations

  1. 1.Department of UrologyGeneral Hospital of Jinan Military CommandJinanChina
  2. 2.Department of UrologyChanghai HospitalShanghaiChina

Personalised recommendations